149 related articles for article (PubMed ID: 31670356)
1. Irreversibility of arsenic trioxide induced PML/RARα fusion protein solubility changes.
Maimaitiyiming Y; Shao YM; Chen WZ; Jiang Y; Bu N; Ma LY; Wang QQ; Lu XY; Naranmandura H
Metallomics; 2019 Dec; 11(12):2089-2096. PubMed ID: 31670356
[TBL] [Abstract][Full Text] [Related]
2. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
[TBL] [Abstract][Full Text] [Related]
3. PRMT5-mediated RNF4 methylation promotes therapeutic resistance of APL cells to As
Huang X; Yang Y; Zhu D; Zhao Y; Wei M; Li K; Zhu HH; Zheng X
Cell Mol Life Sci; 2022 May; 79(6):319. PubMed ID: 35622143
[TBL] [Abstract][Full Text] [Related]
4. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
Sternsdorf T; Puccetti E; Jensen K; Hoelzer D; Will H; Ottmann OG; Ruthardt M
Mol Cell Biol; 1999 Jul; 19(7):5170-8. PubMed ID: 10373566
[TBL] [Abstract][Full Text] [Related]
5. Involvement of PML-I in reformation of PML nuclear bodies in acute promyelocytic leukemia cells by leptomycin B.
Wang C; Su L; Shao YM; Chen WZ; Bu N; Hao R; Ma LY; Hussain L; Lu XY; Wang QQ; Naranmandura H
Toxicol Appl Pharmacol; 2019 Dec; 384():114775. PubMed ID: 31669778
[TBL] [Abstract][Full Text] [Related]
6. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
Chen Z; Chen GQ; Shen ZX; Chen SJ; Wang ZY
Semin Hematol; 2001 Jan; 38(1):26-36. PubMed ID: 11172537
[TBL] [Abstract][Full Text] [Related]
7. [Involvement of PML proteins in treatment of acute promyelocytic leukemia with arsenic trioxide].
Hao R; Su L; Shao Y; Bu N; Ma L; Naranmandura H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2018 May; 47(5):541-551. PubMed ID: 30693698
[TBL] [Abstract][Full Text] [Related]
8. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.
Isakson P; Bjørås M; Bøe SO; Simonsen A
Blood; 2010 Sep; 116(13):2324-31. PubMed ID: 20574048
[TBL] [Abstract][Full Text] [Related]
9. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
Jing Y
Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
[TBL] [Abstract][Full Text] [Related]
10. RXRα ligand Z-10 induces PML-RARα cleavage and APL cell apoptosis through disrupting PML-RARα/RXRα complex in a cAMP-independent manner.
Xu L; Zeng Z; Zhang W; Ren G; Ling X; Huang F; Xie P; Su Y; Zhang XK; Zhou H
Oncotarget; 2017 Feb; 8(7):12311-12322. PubMed ID: 28129653
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
Yan H; Peng ZG; Wu YL; Jiang Y; Yu Y; Huang Y; Zhu YS; Zhao Q; Chen GQ
Haematologica; 2005 Dec; 90(12):1607-16. PubMed ID: 16330433
[TBL] [Abstract][Full Text] [Related]
12. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.
Li K; Wang F; Cao WB; Lv XX; Hua F; Cui B; Yu JJ; Zhang XW; Shang S; Liu SS; Yu JM; Han MZ; Huang B; Zhang TT; Li X; Jiang JD; Hu ZW
Cancer Cell; 2017 May; 31(5):697-710.e7. PubMed ID: 28486108
[TBL] [Abstract][Full Text] [Related]
13. Integrity of zinc finger motifs in PML protein is necessary for inducing its degradation by antimony.
Yang C; Hao R; Lan YF; Chen YJ; Wang C; Bu N; Wang QQ; Hussain L; Ma LY; Maimaitiyiming Y; Lu XY; Naranmandura H
Metallomics; 2019 Aug; 11(8):1419-1429. PubMed ID: 31313788
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic effects of arsenic trioxide on acute promyelocytic leukemia and other types of leukemias.
Yousefnia S
Cell Biol Int; 2021 Jun; 45(6):1148-1157. PubMed ID: 33527587
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z
Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816
[TBL] [Abstract][Full Text] [Related]
16. Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells.
Müller S; Miller WH; Dejean A
Blood; 1998 Dec; 92(11):4308-16. PubMed ID: 9834237
[TBL] [Abstract][Full Text] [Related]
17. Chloroquine aggravates the arsenic trioxide (As2O3)-induced apoptosis of acute promyelocytic leukemia NB4 cells via inhibiting lysosomal degradation in vitro.
Liu DM; Zhang XD; Yang L
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6412-6421. PubMed ID: 30338810
[TBL] [Abstract][Full Text] [Related]
18. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
[TBL] [Abstract][Full Text] [Related]
19. PCGF2 negatively regulates arsenic trioxide-induced PML-RARA protein degradation via UBE2I inhibition in NB4 cells.
Jo S; Lee YL; Kim S; Lee H; Chung H
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt A):1499-509. PubMed ID: 27030546
[TBL] [Abstract][Full Text] [Related]
20. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
